Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms.
AffiliationCRC Department of Medical Oncology, University of Manchester, UK.
MetadataShow full item record
AbstractResults from recent trials challenge the traditional view that chemotherapy offers no survival or quality of life benefits over best supportive care. Meta-analyses of recent trials reveal a modest survival benefit for combination chemotherapy over best supportive care, although there is no strong evidence from randomized trials for superiority of combination over single-agent therapy. In chemotherapy trials where data on performance status change were collected, performance status improved in one-third of patients and remained constant in a further third. Fewer studies have measured changes in specific disease-related symptoms, but there are data from studies with gemcitabine which show improvements in a range of symptoms, including cough, haemoptysis, pain, dyspnoea and anorexia. Thus more patients benefit from chemotherapy than may be suggested by objective response. Surveys have shown that patients are more likely to accept intensive chemotherapy for what are perceived by health care professionals as potentially small benefits. Studies have shown evidence of cost savings associated with chemotherapy over best supportive care.
CitationSymptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. 1995, 6 Suppl 6:39-48 Anticancer Drugs
- Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer.
- Authors: Thatcher N, Jayson G, Bradley B, Ranson M, Anderson H
- Issue date: 1997 Jun
- Current chemotherapy of advanced non-small cell lung cancer.
- Authors: Abratt RP
- Issue date: 1995 Dec
- Update on gemcitabine/carboplatin in patients with advanced non-small cell lung cancer.
- Authors: Harper P
- Issue date: 2003 Aug
- Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer?
- Authors: Gridelli C
- Issue date: 2002 Nov
- Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine.
- Authors: Vansteenkiste J, Vandebroek J, Nackaerts K, Dooms C, Galdermans D, Bosquée L, Delobbe A, Deschepper K, Van Kerckhoven W, Vandeurzen K, Deman R, D'Odemont JP, Siemons L, Van den Brande P, Dams N, Leuven Lung Cancer Group.
- Issue date: 2003 May